Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Cigna Poised For Growth In 2019 On Express Scripts Buyout

By Zacks Investment ResearchStock MarketsDec 27, 2018 11:45PM ET
Cigna Poised For Growth In 2019 On Express Scripts Buyout
By Zacks Investment Research   |  Dec 27, 2018 11:45PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Cigna Corp. (NYSE:CI) looks well poised to growth with the recent acquisition of Express Scripts (NASDAQ:ESRX), the pharmacy benefits manager, which has transformed it into a diversified health services company. The company’s existing businesses — administrative services, international operations, and disability and life insurance — are already performing strongly, and the addition of this new business will make it a sort of one-stop shop of healthcare needs.

The combination of Express Scripts’ pharmacy benefit business with Cigna’s health insurance business will help control drug pricing cost to a large extent, one of the biggest components of soaring medical cost. Cigna has better control over its medical cost than other players in the industry. The decline in medical costs should further aid its margins.

Another distinguishing feature of the company is its international business, which provides additional diversification opportunities. Only another company in the space, UnitedHealth Group, Inc. (NYSE:UNH), has growing international business.

Cigna’s international business, which includes India, Hong Kong, Turkey and the Middle East, among others, has overall recorded double-digit revenue and earnings growth for the past seven years. The biggest international market for Cigna is South Korea, where it has been operating for more than three decades.

Moreover, the company has a chunk of revenues coming from the administrative services only (ASO) business, which though has lower profitability but is growing in size and provides opportunities for cross selling.

Another positive for Cigna is its strong capital position. Its cash flow from operations has been increasing consistently for the past four years and the trend continued in the first nine months of 2018. An increasing cash flow provides scope for investment in business. Though the company’s leverage levels have increased due to the purchase of Express Scripts, the same should moderate by next year as the company repays debt.

Cigna expects adjusted EPS in 2019 to gain in the double-digit range (this excludes any impact from transitioning of clients by Express Scripts specially Anthem (NYSE:ANTM)). By the year 2021, Cigna projects adjusted EPS of $20 to $21, of which $2 to $3 will come from Express Scripts.

In a year's time, shares of the company have lost 6.1% compared with the industry's decline of 23.2%.

Cigna carries a Zacks Rank #2 (Buy). Some other stocks worth considering in the healthcare space are BioTelemetry, Inc. (NASDAQ:BEAT) , Medpace Holdings, Inc. (NASDAQ:MEDP) and AMN Healthcare Servcies Inc. (NYSE:AMN) . While BioTelemetry carries a Zacks Rank #1 (Strong Buy), the other two carries the same Zacks Rank as Cigna. You can see the complete list of today’s Zacks #1 Rank stocks here.

BioTelemetry beat estimates in each of the four quarters with an average positive surprise of 55.6%. Medpace and AMN Healthcare beat estimates in three of the four reported quarters with an average positive surprise of 22.8% and each, 23.97% and 4.17%, respectively.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>

AMN Healthcare Services Inc (AMN): Free Stock Analysis Report

Cigna Corporation (CI): Free Stock Analysis Report

BioTelemetry, Inc. (BEAT): Free Stock Analysis Report

Medpace Holdings, Inc. (MEDP): Free Stock Analysis Report

Original post

Zacks Investment Research
Cigna Poised For Growth In 2019 On Express Scripts Buyout

Related Articles

Cigna Poised For Growth In 2019 On Express Scripts Buyout

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email